ArticleTherapeutic advances in medical oncology2024

Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.

Kimberly M Burcher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.